Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8943930 | 0.72 | — | — | |
| SCHEMBL5726977 | 0.67 | GSK3A (0.40) | GSK3AGSK3B | |
| SCHEMBL29750384 | 0.65 | GSK3A (0.39) | GSK3AGSK3B | |
| Hydrochloric Acid SCHEMBL28537243 | 0.64 | GSK3A (0.37) | GSK3AGSK3B | |
| SCHEMBL11349207 | 0.64 | GSK3A (0.37) | GSK3AGSK3B | |
| Hydrochloric Acid SCHEMBL6025174 | 0.64 | GSK3A (0.37) | GSK3AGSK3B | |
| SCHEMBL2009985 | 0.64 | — | — | |
| SCHEMBL208590 | 0.62 | — | — | |
| SCHEMBL277815 | 0.61 | — | — | |
| SCHEMBL207029 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3094626-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS AS RXR AGONISTS | Connexios Life Sciences Pvt. Ltd. (IN) | 2016-11-23 | — | — | EP | disclosed |
| WO-2015107549-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS AS RXR AGONISTS | CONNEXIOS LIFE SCIENCES PVT. LTD. (IN) | 2015-07-23 | — | — | WO | disclosed |
| US-20070054899-A1 | Aromatase inhibitor compounds and uses thereof | PARALLEL WIRELESS, INC. | 2007-03-08 | — | — | US | disclosed |
| CN-1886403-A | Use of a compound of formula (i) as an inhibitor of aromatase for therapeutic purposes and compounds of formula (1) thereas | YANG JI CHEMICAL COMPANY LTD (KR) | 2006-12-27 | — | — | CN | disclosed |
| EP-1678170-A1 | USE OF A COMPOUND OF FORMULA (I) AS AN INHIBITOR OF AROMATASE FOR THERAPEUTIC PURPOSES AND COMPOUNDS OF FORMULA (1) THEREAS | Yang Ji Chemical Company Ltd. (KR) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005033104-A1 | USE OF A COMPOUND OF FORMULA (I) AS AN INHIBITOR OF AROMATASE FOR THERAPEUTIC PURPOSES AND COMPOUNDS OF FORMULA (1) THEREAS | YANG JI CHEMICAL COMPANY, LTD (KR) | 2005-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054899-A1 | Aromatase inhibitor compounds and uses thereof | CYP19A1, CYP17A1, HSD17B11 | GSK3A 173/4885GSK3B 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.